



BELGIAN WEEK BASL-BLIC MEETING February 1, 2024

BASL-BLIC MEETING: THURSDAY

SESSION 1

08:30-10:00: 12 abstracts (10 min per abstract)

Moderators: Anja Geerts (BASL), Luisa Vonghia (BeLiac)

08:30 84 A 01 Impact of peroxisome proliferator-activated receptor agonists on myosteatosis in the context of metabolic dysfunction-associated steatotic liver disease.

N. BOLIAKI (1), G. HENIN (2), N. LANTHIER (2) / [1] UCL Saint-Luc, Brussels, [2] UCLouvain

08:40 23 A 02 Spatial proteo-transcriptomics identifies macrophage heterogeneity In metabolic dysfunction-associated steatohepatitis.

M. BOESCH (1), A. ANTORANZ-MARTINEZ (1), H. KORF (1),
T. OSTYN (1), T. MY VAN (2), D. NEWHOUSE (2), R. FEIO-AZEVEDO (1),
L. VAN MELKEBEKE (1), L. SMETS (1), M. WALLAYS (1), J. CLARK (3),
A. DALY (3), M. EKSTEDT (4), J. SCHATTENBERG (5), J. BOURSIER (6),
E. BUGIANESI (7), V. RATZIU (8), M. LANNOO (9), E. DELEUS (9),
J. JAEKERS (9), H. TOPAL (9), B. TOPAL (9), B. BOECKX (10),
J. VERBEEK (1), F. BOSISIO (1), D. LAMBRECHTS (10), T. ROSKAMS (1),
S. FRANCQUE (11), A. HÄRTLOVA (12), D.TINIAKOS (3), Q. ANSTEE (3),
S. VAN DER MERWE (1), O. GOVAERE (1) / [1] KULeuven,
[2] NanoString Technologies, USA, [3] Newcastle University, UK,
[4] Linköping University, Sweden, [5] University Hospital Mainz,
Germany, [6] Angers University Hospital, France, [7] University of
Turin, Italy, [8] Sorbonne Université, France, [9] UZ Leuven, [10]

KULeuven, [11] UZ Antwerpen, [12] University of Gothenburg, Sweden

- 08:50** 33 A 03 **Exploring the impact of dietary patterns and ultra-processed food consumption on the severity of biopsy-proven steatotic liver disease.**
S. DECLERCK (1), G. HENIN (1), S. ANDRÉ-DUMONT (2),
A. GOFFAUX (1), A. LOUMAYE (2), P. BALDIN (2), P. HENRY (3),
P. STÄRKEL (2), N. LANTHIER (2) / [1] UCLouvain, Brussels, [2] UCL Saint-Luc, Brussels, [3] IPG, Charleroi
- 09:00** 51 A 04 **GPR176 Expression Correlates with Hepatic Stellate Cell Activation in Metabolic Dysfunction-Associated Steatotic Liver Disease and Chronic Viral Hepatitis.**
V. DE SMET (1), E. GÜRBÜZ (1), N. EYSACKERS (1), A. SMOUT (1),
P. LEFESVRE (2), N. MESSAOUDI (2), H. REYNAERT (2),
I. MANNAERTS (1), S. VERHULST (1), L. VAN GRUNSVEN (1) / [1] VUB, Jette, [2] UZ Brussel
- 09:10** 206 A 05 **The natural history of metabolic dysfunction-associated steatotic liver disease with advanced fibrosis.**
Z. GADI / UZ Antwerpen
- 09:20** 132 A 06 **Comparison of two methods for hepatic venous pressure gradient measurement: the push-wedge versus balloon-occlusion technique.**
N. GESTELS, W. KWANTEN, J. DERDEYN, T. STEINHAUSER,
L. VONGHIA, S. FRANCQUE, T. VANWOLLEGHEM / UZ Antwerpen
- 09:30** 165 A 07 **Harnessing Immune Dysregulation in the Search for Serum Biomarkers for Primary Sclerosing Cholangitis.**
L. HEYERICK, K. DE MUYNCK, Z. DE VOS, S. LEFERE, A. GEERTS,
S. RAEVENS, X. VERHELST, H. VAN VLIERBERGHE, L. DEVISSCHER /
U Gent

- 09:40** 148 A 08 **The Niche Map of Ductular Reaction-driven regeneration.**
R. MANCO (1), G. NEIRYNCK (1), I. LECLERCQ (1) / [1] Institut de Recherche Expérimentale et Clinique, Woluwe-Saint-Lambert
- 09:50** 177 A 09 **Performing Spleen Stiffness Measurement in Routine Clinical Practice: First experiences in a Monocentric Set-Up.**
L. SCHOENMAKERS (1), L. VONGHIA (1), Z. GADI (1), J. DERDEYN (1), T. STEINHAUSER (1), T. VANWOLLEGHEM (1), W. VERLINDEN (2), S. FRANQUE (1), W. KWANTEN (1) / [1] UZ Antwerpen, [2] Vitaz, Sint-Niklaas
- 10:00** 218 A 10 **Hepatitis B seroprevalence in Belgium anno 2020.**
A. FURQUIM D'ALMEIDA (1), E. HO (2), C. SCHÜTTLER (3), P. BEUTELS (1), P. VAN DAMME (1), N. HENS (1), H. THEETEN (1), T. VANWOLLEGHEM (1) / [1] U Antwerpen, [2] UZ Antwerpen, [3] Justus Liebig University, Giessen, Germany
- 10:10** 179 A 11 **Insufficient implementation of pretherapeutic hepatitis B and C screening guidelines in one non-academic Belgian hospital: The CHOICe Trial (Chronic Hepatitis B/C screening in patients On Immunosuppressive therapy and Chemotherapy).**
M. COESSENS, W. VERLINDEN, J. SCHOUTEN / Vitaz, Sint-Niklaas
- 10:20** 160 A 12 **Synergistic ligand combinations of peroxisome proliferator-activated receptor alpha and estrogen-related receptor alpha ameliorate MASLD.**
M. ANTWI, S. LEFERE, L. KOORNEEF, A. HELDENS, K. DECROIX, L. ONGHENA, J. THOMMIS, A. GEERTS, L. DEVISSCHER, K. DE BOSSCHER / U Gent

10:30-10:45 Coffee break

10:45-11:15

Moderator: TBC (BeLIAC)

10:45 **BELIAC lecture: Current Status of intestinal and combined liver**

intestinal transplantation.

Jacques Pirenne (KUL)

SESSION 2:

11:15-12:30 6 abstracts (12 min per abstract)

Moderators: Pierre Deltenre(BASL), Jef Verbeek (BeLIAC)

- 11:15 106 A 13 The double-edged sword of bariatric surgery: extending the excluded Limb can trigger bacterial translocation, liver inflammation and death.**
L. ONGHENA, A. HELDENS, M. ANTWI, L. DEVISSCHER, H. VAN VLIERBERGHE, S. RAEVENS, X. VERHELST, A. HOORENS, Y. VAN NIEUWENHOVE, A. GEERTS, S. LEFERE / UZ Gent
- 11:27 9 A 14 Spleen stiffness-based algorithms are superior to Baveno VI criteria to rule-out varices needing treatment in patients with advanced chronic liver disease.**
E. VANDERSCHUEREN (1), A. ARMANDI (2), W. KWANTEN (3), D. CASSIMAN (4), S. FRANCCQUE (3), J. SCHATTENBERG (5), W. LALEMAN (4) / [1] KU Leuven, [2] University of Turin, Italy, [3] UZ Antwerpen, [4] UZ Leuven [5] University Medical Center of the Johannes Gutenberg University, Germany,
- 11:39 73 A 15 Semaglutide-loaded lipid nanocapsules effect on metabolic dysfunction- associated steatotic liver.**
I. DOMINGUES, H. YAGOUBI, W. ZHANG, V. MAROTTI, E. K KAMBALE, A. BELOQUI, I. LECLERCQ / UCLouvain, Brussels
- 11:51 24 A 16 Portal vein recanalization in non-cirrhotic patients with portal vein occlusion: first results of a VALDIG study.**
K. TROCH (1), A. DENYS (2), M. PRAKTIKNJO (3), A. BAIGES (4), F. TURON (4), L. ELKRIEF (5), A. PLESSIER (6), B. GUIU (7), F. ARTRU (2), V. FRAITZL (3), J. GARCIA-PAGAN (4), O. POL (4), M. DIOGUARDI BURGIO (6), M. MESZAROS (7), M. BARRUFET (4), M. BURREL (4), M. GARCIA-CRIADO (4), A. SOLER (4), L. D'ALTEROCHE (5), A. MAROT (8), P. DELTENRE (9) / [1] UCL Saint-Luc Bouge, Namur, [2] CHUV, Lausanne, Switzerland,

[3] Universitatsklinikum Munster, Germany, [4] Hospital Clinic Barcelona, Spain, [5] CHU de Tours, France, [6] Hopital Beaujon (AP-HP), France, [7] St-Eloi University Hospital, France, [8] CHU-UCL Godinne, [9] Clinique Saint-Luc Bouge; CHU UCL Namur; CUB Erasme

12:03 79 A 17 **Mitochondrial dysfunction characterizes the deleterious transgenerational effects of maternal obesity on MASLD in mice and non-human primates.**

A. HELDENS (1), M. ANTWI (1), L. ONGHENA (1), J. NORLIN (2), L. DEVISSCHER (1), X. VERHELST (1), S. RAEVENS (1), H. VAN VLIERBERGHE (1), R. DE BRUYNE (1), A. GEERTS (1), S. LEFERE (1) / [1] U Gent [2] Novo Nordisk, Copenhagen, Denmark

12:15 213 A 18 **Phosphatidylethanol complements urinary and scalp hair ethyl glucuronide in the detection of alcohol use in patients with alcohol-related cirrhosis.**

B. VANLERBERGHE (1), C. DUMITRASCU (2), N. VAN DEN EEDE (1), F. NEVENS (1), A. VAN NUIJS (2), J. VERBEEK (1) / [1] UZ Leuven, [2] U Antwerpen

12:30-13:30 Lunch

SESSION 3:

13:30-14:50 4 abstracts (10 min per abstract) + Hautekeete lecture

Moderators: Wim Laleman (BASL), Caroline Amicone (BeLIAC)

13:30 107 A 19 **Bariatric surgery is a major independent factor of disease progression in cirrhotic patients with alcohol-related liver disease.**

L. ONGHENA, L. DEMEULENAERE, L. DEVISSCHER, H. VAN VLIERBERGHE, S. RAEVENS, X. VERHELST, Y. VAN NIEUWENHOVE, S. LEFERE, A. GEERTS / UZ Gent

13:40 55 A 20 **Creation of crackers enriched with polyunsaturated fatty acids with benefits for metabolic parameters: a double-blind randomised controlled trial in overweight subjects.**

C. DÉNOS (1), B. PACHIKIAN (1), S. HDIDOU (1), E. DIERGE (1), C. DEBIER (1), P. TREFOIS (2), Y. LARONDELLE (1), N. LANTHIER (2) /

[1] UCLouvain, Brussels, [2] UCL Saint-Luc, Brussels

13:50 59 A 21 **Telomere Length is Significantly Reduced in Alcohol-Associated Hepatitis.**
D. PENRICE, JALAN-SAKRIKAR, B. KASSMEYER, P. KAMATH, V. SHAH, D. SIMONETTO / Mayo Clinic, Rochester, USA

14:00 69 A 22 **Bariatric surgery post-liver transplantation: a Belgian nationwide study.**
L. ONGHENA (1), A. GEERTS (1), F. BERREVOET (1), J. PIRENNE (2), J. VERBEEK (2), E. BONACCORSI-RIANI (3), G. DAHLQVIST (3), L. VONGHIA (4), O. DETRY (5), J. DELWAIDE (5), S. LEFERE (1), Y. VAN NIEUWENHOVE (1) / [1] UZ Gent, [2] UZ Leuven
[3] UCL Saint-Luc, Brussels, [4] UZ Antwerpen, [5] CHU Liège

Moderator: Thomas Vanwolleghem (UZ Antwerpen)

14:10 **MARC HAUTEKEETE LECTURE: The LiverRisk score predicts long-term liver-related outcomes in the general population.**
Miquel Serra Burriel (Zurich, Switzerland)

14:50-15:30 Coffee break

Session 4:

15:30-17:20 11 abstracts (10 min per abstract)

Moderators: Jean Delwaide (BASL) and Geraldine Dahlqvist (BeLIAC)

15:30 145 A 23 **Spatial Mapping of the Fibrotic Response in a Mouse Model of Alagille Syndrome.**
S. VERHULST (1), F. HILDEBRANDT (2), L. SEVENANTS (3), J. ANKARKLEV (2), L. VAN GRUNSVEN (1), E. ANDERSSON (3), N. VAN HUL (3) / [1] VUB, Jette, [2] Stockholm University, Sweden, [3] Karolinska University Hospital, Sweden

15:40 54 A 24 **Frailty in MASLD patients is associated with the presence of Diabetes and the degree of liver fibrosis.**
S. DECLERCK (1), G. HENIN (1), S. ANDRÉ-DUMONT (2),

A. GOFFAUX (1), G. DAHLQVIST (2), A. LOUMAYE (2),
E. PENDEVILLE (2), T. LEJEUNE (2), M. VALET (1), N. LANTHIER (2) /
[1] UCLouvain, Brussels, [2] UCL Saint-Luc, Brussels

- 15:50** 144 A 25 **Cell Communication Network in Diseased Livers Reveals Lymphotoxin Beta as a Potential Inducer of Hepatic Stellate Cell Activation.**
S. VERHULST, V. MERENS, A. SMOUT, L. VAN GRUNSVEN / VUB, Jette
- 16:00** 85 A 26 **The role of iron-catalyzed ferroptotic cell death in an experimental model of metabolic dysfunction-associated steatohepatitis.**
C. PELEMAN / U Antwerpen
- 16:10** 62 A 27 **An external multicentric validation of the IAIHG autoimmune hepatitis response criteria.**
L. GROSSAR (1), S. RAEVENS (1), C. VAN STEENKISTE (2), I. COLLE (3), C. DE VLOO (4), H. ORLENT (5), J. SCHOUTEN (6), M. GALLANT (7), A. VAN DRIESSCHE (8), S. LEFERE (1), L. DEVISSCHER (9),
A. GEERTS (1), H. VAN VLIERBERGHE (1), X. VERHELST (1) / [1] UZ Gent, [2] Maria Middelaars Ziekenhuis, Gent, [3] ASZ, Aalst, [4] AZ Delta, Roeselare, [5] AZ Sint-Jan Brugge-Oostende, Brugge, [6] AZ Nikolaas, Sint-Niklaas, [7] Jan Yperman Hospital, Ieper, [8] AZ Glorieux Ronse, [9] U Gent
- 16:20** 202 A 28 **A Non-Invasive Score Model for Prediction of Significant Fibrosis And Fibrotic MASH Based on Serum Biomolecules.**
N. BEYENE (1), W. KWANTEN (2), J. DERDEYN (2), T. STEINHAUSER (2), T. VANWOLLEGHEM (2), A. DRIESSEN (2), S. FRANCQUE (2),
L. VONGHIA (2) / [1] U Antwerpen, [2] UZ Antwerpen
- 16:30** 149 A 29 **Pre-treatment serum N-glycans predict poor immunotherapy response and survival in Hepatocellular Carcinoma.**
N. SOMERS (1), E. BUTAYE (1), L. GROSSAR (1),
H. VAN VLIERBERGHE (1), A. GEERTS (1), S. RAEVENS (1),

S. LEFERE (2), L. DEVISSCHER (2), L. MEURIS (2), N. CALLEWAERT (2),
R. MOHR (3), X. VERHELST (1) / [1] UZ Gent, [2] U Gent [3] Charité
University Hospital, Berlin, Germany

16:40 101 A 30 **Transition from non-alcoholic fatty liver disease to steatotic liver disease: real-world evidence in a cohort of individuals with type 1 and type 2 diabetes.**

J. MERTENS (1), T. HUYBRECHTS (2), E. DIRINCK (1), L. VONGHIA (1),
K. WILHELMUS J. (1), W. VAN HUL (2), C. DE BLOCK (1),
S. FRANCQUE (1) / [1] UZ Antwerpen [2] U Antwerpen

16:50 8 A 31 **The Toulouse algorithm identifies patients with an increased risk of cardiac decompensation only in patients with TIPS for refractory ascites.**

E. VANDERSCHUEREN, Y. BEKHUIS, J. CLERICK, P. MEERSSEMAN,
A. WILMER, E. CLAUS, L. BONNE, G. CLAESSEN, C. VERSLYPE,
G. MALEUX, W. LALEMAN / UZ Leuven

17:00 56 A 32 **Development of microenvironment-dependent hepatocellular carcinoma and colorectal liver metastasis spheroid culture models.**

E. KNETEMANN (1), A. HERRERO (2), L. VAN GRUNSVEN (1),
I. MANNAERTS (1) / [1] VUB, Jette, [2] University of the Basque
Country, Spain

17:10 34 A 33 **Liver elasticity evolution in metabolic dysfunction-associated steatotic liver disease patients: a real-life prospective study.**

J. SCHOLTENS, S. ANDRÉ-DUMONT, G. HENIN, G. DAHLQVIST,
N. LANTHIER / UCL Saint-Luc, Brussels

17:20-17:50 BASL Best Basic Prize
BASL Best Clinical Prize
BASL General assembly
Thomas Vanwolleghem (BASL)

e-POSTERS:

- 20 A 34 **Gut microflora composition in patients with non-alcoholic fatty liver disease.**
T. KHACHIDZE (1), G. BARBAKADZE (2) / [1] Grigol Robakidze University, Tbilisi, Georgia
- 40 A 35 **Prevalence of HCV, HBV and HIV in a psychiatric centre in Belgium.**
L. SEYNHAEVE (1), J. DECAESTECKER (2), C. DE VLOO (2), L. HARLET (2),
J. DEWYSPELAERE (2), W. DE TROYER (3), K. NEYRINCK (3),
K. FERDINANDE (2) / [1] AZ Delta, Roeselare, [2] AZ Delta, Roeselare,
[3] Psychiatrisch Centrum O.L.V. van Vrede Menen
- 57 A 36 **Long-term histological fibrosis reduction following SVR in HCV-recurrence after liver transplantation.**
T. LEMMENS, G. HENIN, S. AYDIN, P. BALDIN, Y. HORMANS, G. DAHLQVIST /
UCL Saint Luc, Brussels
- 125 A 37 **Hepatitis C among drug users in Charleroi: the other side of the Opioid Crisis.**
H. CHERKAOUI, E. TOUSSAINT, D. BLERO, W. SOUB DEFEU / Hôpital Civil Marie Curie, Lodelinsart
- 126 A 38 **Hepatitis C: differences between the North and the South.**
H. CHERKAOUI (1), N. LAHMIDANI (2), A. MEKKAOUI (2), D. BENAHAH (2),
S. IBRAHIMI (2), M. ABKARI (2), E. TOUSSAINT (1), W. SOUB DEFEU (1),
H. ABID (2) / [1] Hôpital Civil Marie Curie, Lodelinsart, [2] University Hospital Hassan II, Fez, Morocco
- 128 A 39 **Factors in poor response to ursodesoxycholic acid in primary biliary cholangitis.**
H. CHERKAOUI (1), N. LAHMIDANI (2), A. MEKKAOUI (2), D. BENAHAH (2),
M. EL YOUSFI (2), S. IBRAHIMI (2), M. ABKARI (2), H. ABID (2) / [1] Hôpital Civil Marie Curie, Lodelinsart, [2] University Hospital Hassan II, Fez, Morocco
- 143 A 40 **Metabolic associated steatohepatitis is associated to NO-dependent endothelial dysfunction in mice.**
J. LALLEMENT / UCLouvain, Brussels
- 181 A 41 **Hepatitis C lost-to-follow-up in Primary Care - HeLP project.**
M. COESSENS, J. SCHOUTEN, W. VERLINDEN / Vitaz, Sint-Niklaas